Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1

Le Traitement Par Lenvatinib + Anti-PD1 Du Mélanome Métastatique

The hypothesis is that treatment with Lenvatinib + Pembrolizumab is less effective in real life than in clinical trials. In fact, an objective response rate < 20% and a worse tolerability of the treatment in real life with ≥50% of severe toxicities are expected.

Inclusion Criteria:

• Metastatic melanoma (stage III non operable or stage IV according to American Joint Committee on Cancer staging rules) refractory to immunotherapy (≥ 2nd treatment line after minimum a failure of immunotherapy)

Exclusion Criteria:

• Uveal melanoma